New Stock News | Jiangxi Biopharmaceutical Port IPO prospectus invalid
Jiangxi Biopark's IPO prospectus is invalid.
Jiangxi Biotech Research Institute Co., Ltd. (referred to as Jiangxi Bio) submitted its Hong Kong IPO prospectus on April 11, which expired after 6 months on October 11, with CICC and CMSC International as joint sponsors when submitting the application.
According to the prospectus, based on data from Frost & Sullivan, Jiangxi Bio is the largest provider of human tetanus antitoxin (TAT) in China and globally, with market shares of 65.8% and 36.6% by sales in 2024. Tetanus antitoxin is a type of antiserum that neutralizes the toxin produced by the bacterium that causes tetanus, providing immediate protection and treatment to prevent and treat tetanus infections.
Related Articles

POWER XINCHEN (01148) will be temporarily suspended from trading starting October 16th, awaiting the publication of insider information.

AFFLUENT FDN (01757) will be temporarily suspended from trading starting from October 16th, pending the release of insider information.

POWER XINCHEN (01148) Will be temporarily suspended from trading starting from October 16th. The reason will be announced later.
POWER XINCHEN (01148) will be temporarily suspended from trading starting October 16th, awaiting the publication of insider information.

AFFLUENT FDN (01757) will be temporarily suspended from trading starting from October 16th, pending the release of insider information.

POWER XINCHEN (01148) Will be temporarily suspended from trading starting from October 16th. The reason will be announced later.
